Valion Bio Advances Entolimod Program with Government Engagement, Manufacturing Scale-Up, Oncology Supportive Care Plans
MT Newswires Live
Jul 14
Valion Bio (VBIO) said Tuesday that it has advanced its Entolimod program through expanded US government engagement, a 200-fold manufacturing scale-up and plans to enter oncology supportive care.
The company said it continues discussions with BARDA, NIAID, AFRRI and the Department of Defense on Acute Radiation Syndrome preparedness, while also engaging with Ukraine on potential stockpiling.
Valion Bio said its unit, Velocity Bioworks, has completed a 200-fold manufacturing scale-up of Entolimod, equivalent to 1.3 million potential doses.
The company said it also plans physician-sponsored studies evaluating Entolimod for chemotherapy-related neutropenia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.